Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)

v3.21.2
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Jun. 30, 2021
Business Combination, Contingent Consideration, Liability, Total $ 22,600  
Fair Value, Recurring [Member]    
Derivative instruments - cash flow hedges 533 $ 275
Total assets 39,273 32,738
Business Combination, Contingent Consideration, Liability, Total 22,600 29,400
Derivative instruments - cash flow hedges 6,435 8,376
Total liabilities 29,035 37,776
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Derivative instruments - cash flow hedges 0 0
Total assets 37,229 31,081
Business Combination, Contingent Consideration, Liability, Total 0 0
Derivative instruments - cash flow hedges 0 0
Total liabilities 0 0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Derivative instruments - cash flow hedges 533 275
Total assets 2,044 1,657
Business Combination, Contingent Consideration, Liability, Total 0 0
Derivative instruments - cash flow hedges 6,435 8,376
Total liabilities 6,435 8,376
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Derivative instruments - cash flow hedges 0
Total assets 0 0
Business Combination, Contingent Consideration, Liability, Total 22,600 29,400
Derivative instruments - cash flow hedges 0 0
Total liabilities 22,600 29,400
Equity Securities [Member] | Fair Value, Recurring [Member]    
Investments, Fair Value Disclosure [1] 25,240 19,963
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 23,729 18,581
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 1,511 1,382
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0 0
Certificates of Deposit [Member] | Fair Value, Recurring [Member]    
Investments, Fair Value Disclosure [2] 13,500 12,500
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 13,500 12,500
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0 0
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0 $ 0
[1] Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) at September 30, 2021 and June 30, 2021 was $6.6 million and $6.6 million, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.5 million and $1.4 million as of September 30, 2021 and June 30 2021, respectively.
[2] Included in available-for-sale investments on the balance sheet. The certificates of deposit have contractual maturity dates within one year.